Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBITDA Margin (2020 - 2025)

Silence Therapeutics' EBITDA Margin history spans 6 years, with the latest figure at 166076.47% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 16588737.0% to 166076.47% in Q4 2025 year-over-year; TTM through Dec 2025 was 4140.19%, a 411677.0% decrease, with the full-year FY2025 number at 3962.43%, down 393674.0% from a year prior.
  • EBITDA Margin hit 166076.47% in Q4 2025 for Silence Therapeutics, up from 16505.66% in the prior quarter.
  • Over the last five years, EBITDA Margin for SLN hit a ceiling of 166076.47% in Q4 2025 and a floor of 389226869.46% in Q3 2021.
  • Historically, EBITDA Margin has averaged 19455856.0% across 5 years, with a median of 358.32% in 2021.
  • Biggest five-year swings in EBITDA Margin: crashed 2000000000bps in 2021 and later skyrocketed 2000000000bps in 2022.
  • Tracing SLN's EBITDA Margin over 5 years: stood at 329.91% in 2021, then surged by 30bps to 230.03% in 2022, then plummeted by -175bps to 633.59% in 2023, then soared by 130bps to 189.1% in 2024, then surged by 87726bps to 166076.47% in 2025.
  • Business Quant data shows EBITDA Margin for SLN at 166076.47% in Q4 2025, 16505.66% in Q3 2025, and 11981.5% in Q2 2025.